Immune Pharmaceuticals Inc. (the "Company") announced today that on October 19, 2017, Nasdaq First North Stockholm (the "Exchange") halted trading in the Company's shares pending the Company's providing public disclosure in Sweden regarding its current financial position.
Immune Pharmaceuticals Inc. announces pricing of $18,000,000 public offering of convertible preferred stock and warrants
ENGLEWOOD CLIFFS, N.J., (BUSINESS WIRE) - Immune Pharmaceuticals Inc. ("Immune") (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the pricing of an underwritten public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune.
Poster demonstrates activity of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis
Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
Results from six subjects demonstrate a large and statistically significant reduction in bullous pemphigoid activity despite aggressive prednisone tapering, with no serious adverse events.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") provided the following R&D and business update and summary of recent financial highlights.
CYTOVIA Inc, IMMUNE Pharma's Oncology subsidiary, announces publication of results showing anti-metastatic properties of its lead drug Ceplene® and filing of a new worldwide patent
Additional potential in cancer immunotherapy with Ceplene in combination with Interleukin-15 (IL-15)
Immune Pharmaceuticals Inc. (NASDAQ; IMNP) a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immuno-inflammation, dermatology and immuno-oncology, issued the following Letter to Shareholders.
Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company
Immune shareholders to receive additional pro rata shares in Cytovia
IMMUNE Pharmaceuticals' Oncology subsidiary, CYTOVIA, announces the filing of a world-wide patent protecting the use of Ceplene® in acute myeloid leukemia (AML) and other hematological cancers with mutated NPM1
Favorable relapse-free and overall survival in AML patients with persistent leukemic cells
Cytovia Inc, Immune Pharmaceuticals' Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America
Cytovia Inc. ("Cytovia") the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a licensing agreement with Pint Pharma International S.A. ("Pint") a pharmaceutical company focused on Latin America and other markets, for the marketing and distribution of Ceplene throughout Latin America (the "territory"). Pint Gmbh will separately enter into an investment agreement, which will lead to an investment of $4 million into Cytovia. Dr. Massimo Radaelli, Executive Chairman of Pint, will also join the board of Cytovia upon completion of the investment and effective spin off of Cytovia from Immune.
Immune Pharmaceuticals Inc
Marknadsplats: First North
Interim Report Q2 2016